Skip to Content

Generic Rasuvo Availability

Rasuvo is a brand name of methotrexate, approved by the FDA in the following formulation(s):

RASUVO (methotrexate - solution;subcutaneous)

  • Manufacturer: MEDAC PHARMA INC
    Approval date: July 10, 2014
    Strength(s): 7.5MG/0.15ML (7.5MG/0.15ML), 10MG/0.20ML (10MG/0.20ML), 12.5MG/0.25ML (12.5MG/0.25ML), 15MG/0.30ML (15MG/0.30ML), 17.5MG/0.35ML (17.5MG/0.35ML), 20MG/0.4ML (20MG/0.4ML), 22.5MG/0.45ML (22.5MG/0.45ML), 25MG/0.5ML (25MG/0.5ML), 27.5MG/0.55ML (27.5MG/0.55ML), 30MG/0.6ML (30MG/0.6ML)

Has a generic version of Rasuvo been approved?

No. There is currently no therapeutically equivalent version of Rasuvo available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rasuvo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Concentrated methotrexate solutions
    Patent 8,664,231
    Issued: March 4, 2014
    Assignee(s): Medac Gesellschaft fuer Klinische Spezialpraepararate mbH
    Concentrated methotrexate solutions are described which are suitable for the use of an active substance in the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically acceptable solvent at a concentration of more than 30 mg/ml. The invention also relates to a ready-made syringe and a carpule containing such a pharmaceutical solution formulation, as well as a pen injector comprising such a carpule and/or a ready-made syringe.
    Patent expiration dates:
    • June 1, 2029
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.